CN104508143A - 用于急性髓细胞白血病的诊断、预后和治疗的方法和组合物 - Google Patents

用于急性髓细胞白血病的诊断、预后和治疗的方法和组合物 Download PDF

Info

Publication number
CN104508143A
CN104508143A CN201380024896.0A CN201380024896A CN104508143A CN 104508143 A CN104508143 A CN 104508143A CN 201380024896 A CN201380024896 A CN 201380024896A CN 104508143 A CN104508143 A CN 104508143A
Authority
CN
China
Prior art keywords
patient
sudden change
mll
dnmt3a
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380024896.0A
Other languages
English (en)
Chinese (zh)
Inventor
罗斯·L·莱文
奥马尔·阿卜杜勒-瓦希卜
杰伊·P·帕特尔
米特哈特·戈嫩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN104508143A publication Critical patent/CN104508143A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380024896.0A 2012-03-12 2013-03-11 用于急性髓细胞白血病的诊断、预后和治疗的方法和组合物 Pending CN104508143A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261609723P 2012-03-12 2012-03-12
US61/609,723 2012-03-12
PCT/US2013/030208 WO2013138237A1 (en) 2012-03-12 2013-03-11 Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
CN104508143A true CN104508143A (zh) 2015-04-08

Family

ID=49161688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380024896.0A Pending CN104508143A (zh) 2012-03-12 2013-03-11 用于急性髓细胞白血病的诊断、预后和治疗的方法和组合物

Country Status (7)

Country Link
US (1) US20150031641A1 (enExample)
EP (1) EP2825669A4 (enExample)
JP (1) JP2015512630A (enExample)
CN (1) CN104508143A (enExample)
AU (1) AU2013232379A1 (enExample)
CA (1) CA2867375A1 (enExample)
WO (1) WO2013138237A1 (enExample)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104774954A (zh) * 2015-04-23 2015-07-15 上海允英医疗科技有限公司 用于hras突变检测的引物、探针及检测试剂盒
CN105861674A (zh) * 2016-04-27 2016-08-17 上海荻硕贝肯生物科技有限公司 用于检测与aml预后相关的基因突变的引物、试剂盒及方法
CN105969892A (zh) * 2016-07-14 2016-09-28 北京大学人民医院 Csrp2在作为评估成人b-all患者预后风险标记物中的应用
CN106381332A (zh) * 2016-08-31 2017-02-08 天津协和华美医学诊断技术有限公司 一种检测aml相关基因群的检测试剂盒
WO2017084027A1 (zh) * 2015-11-17 2017-05-26 安诺优达基因科技(北京)有限公司 一种用于急性髓细胞白血病预后分层的试剂盒及检测方法
CN107641650A (zh) * 2017-08-24 2018-01-30 中国人民解放军总医院 Nr1h3在急性髓系白血病精准靶向检测及预后评估中的应用
CN107841556A (zh) * 2017-12-19 2018-03-27 武汉大学 一种基于C/EBPα和IGF1R基因筛选药物发育毒性的试剂盒及应用
CN107893118A (zh) * 2017-12-25 2018-04-10 合肥艾迪康临床检验所有限公司 检测phf6点突变的方法和引物
CN109172597A (zh) * 2018-09-06 2019-01-11 清华大学深圳研究生院 调节rDNA基因染色质组蛋白甲基化水平的物质及其应用
CN110124038A (zh) * 2019-05-08 2019-08-16 山东大学齐鲁医院 腺苷酸琥珀酸合成酶基因和/或其编码的蛋白的新应用
CN111560438A (zh) * 2020-06-11 2020-08-21 迈杰转化医学研究(苏州)有限公司 检测aml预后相关基因突变的引物组合物、试剂盒及其应用
CN112626215A (zh) * 2020-12-30 2021-04-09 武汉康圣达医学检验所有限公司 Aml预后相关基因表达检测试剂盒
CN112708675A (zh) * 2020-12-25 2021-04-27 中山大学肿瘤防治中心 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用
CN113764038A (zh) * 2021-08-31 2021-12-07 华南理工大学 构建骨髓增生异常综合征转白基因预测模型的方法
CN115216541A (zh) * 2021-04-15 2022-10-21 复旦大学附属华山医院 一组白血病标志物及应用
CN115323051A (zh) * 2022-02-22 2022-11-11 天津见康华美医学诊断技术有限公司 一种急性髓系白血病检测探针组合物及其应用
CN115414376A (zh) * 2015-11-11 2022-12-02 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220070066A (ko) 2014-03-14 2022-05-27 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
EP3224380A1 (en) 2014-11-25 2017-10-04 The Broad Institute Inc. Clonal haematopoiesis
EP3626832B1 (en) 2014-11-25 2024-06-12 The Brigham and Women's Hospital, Inc. Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease
PT3362065T (pt) 2015-10-15 2024-06-21 Servier Lab Terapia de combinação compreendendo ivosidenib, citarabina e daunorubicina ou idarubicina para o tratamento de leucemia mielóide aguda
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
EP3383400B1 (en) * 2015-12-04 2022-01-05 Les Laboratoires Servier Methods of treatment of malignancies
KR101877607B1 (ko) * 2016-03-03 2018-07-12 포항공과대학교 산학협력단 인슐린／ｉｇｆ―1 수용체 결핍 돌연변이체의 발달결함만 특이적으로 억제된 예쁜꼬마선충
AU2017353925A1 (en) * 2016-11-02 2018-09-27 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
US10460446B2 (en) * 2017-10-16 2019-10-29 Nant Holdings Ip, Llc Image-based circular plot recognition and interpretation
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2021209517A1 (en) * 2020-04-15 2021-10-21 Centre National De La Recherche Scientifique Prognosis method of acute myeloid leukaemia
KR102317670B1 (ko) * 2020-07-30 2021-10-26 서울대학교산학협력단 Phf6를 표적으로 하는 히스톤 h2b 에피제네틱 조절제 스크리닝 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919623A (en) * 1994-04-27 1999-07-06 St. James's And Seacroft University Hospitals Nhs Trust Nucleic acid mutation assays
JP5937520B2 (ja) * 2010-02-12 2016-06-22 イプソゲン 骨髄性腫瘍の新規診断マーカーとしてのａｓｘｌ１
JP6054303B2 (ja) * 2010-12-30 2016-12-27 ファウンデーション メディシン インコーポレイテッドＦｏｕｎｄａｔｉｏｎ Ｍｅｄｉｃｉｎｅ， Ｉｎｃ． 腫瘍試料の多重遺伝子分析の最適化

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHOU ET AL: "Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations.", 《BLOOD》 *
DICKER F ET AL: "Mutation analysis for RUNX1,MLL-PTD,FLT3-ITD,NPM1 and NRAS in 269 patients with MDS or secondary AML", 《LEUKEMIA》 *
GREEN ET AL: "The prognostic significance of IDH2 mutations in AML depends on the location of the mutation", 《BLOOD》 *
SAHAR BARJESTEH VAN WAALWIJK VAN DOORN-KHOSROVANI1 ET AL: "Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML", 《THE HEMATOLOGY JOURNAL》 *
SHEN ET AL: "Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia", 《BLOOD》 *
VALK ET AL: "Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia.", 《N ENGL J MED》 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104774954A (zh) * 2015-04-23 2015-07-15 上海允英医疗科技有限公司 用于hras突变检测的引物、探针及检测试剂盒
CN115414376A (zh) * 2015-11-11 2022-12-02 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
WO2017084027A1 (zh) * 2015-11-17 2017-05-26 安诺优达基因科技(北京)有限公司 一种用于急性髓细胞白血病预后分层的试剂盒及检测方法
CN105861674A (zh) * 2016-04-27 2016-08-17 上海荻硕贝肯生物科技有限公司 用于检测与aml预后相关的基因突变的引物、试剂盒及方法
CN105969892B (zh) * 2016-07-14 2019-07-19 北京大学人民医院 Csrp2在作为评估成人b-all患者预后风险标记物中的应用
CN105969892A (zh) * 2016-07-14 2016-09-28 北京大学人民医院 Csrp2在作为评估成人b-all患者预后风险标记物中的应用
CN106381332A (zh) * 2016-08-31 2017-02-08 天津协和华美医学诊断技术有限公司 一种检测aml相关基因群的检测试剂盒
CN107641650A (zh) * 2017-08-24 2018-01-30 中国人民解放军总医院 Nr1h3在急性髓系白血病精准靶向检测及预后评估中的应用
CN107641650B (zh) * 2017-08-24 2020-05-08 中国人民解放军总医院 Nr1h3在急性髓系白血病精准靶向检测及预后评估中的应用
CN107841556A (zh) * 2017-12-19 2018-03-27 武汉大学 一种基于C/EBPα和IGF1R基因筛选药物发育毒性的试剂盒及应用
CN107841556B (zh) * 2017-12-19 2020-12-01 武汉大学 一种基于C/EBPα和IGF1R基因筛选药物发育毒性的试剂盒及应用
CN107893118A (zh) * 2017-12-25 2018-04-10 合肥艾迪康临床检验所有限公司 检测phf6点突变的方法和引物
CN109172597A (zh) * 2018-09-06 2019-01-11 清华大学深圳研究生院 调节rDNA基因染色质组蛋白甲基化水平的物质及其应用
CN110124038A (zh) * 2019-05-08 2019-08-16 山东大学齐鲁医院 腺苷酸琥珀酸合成酶基因和/或其编码的蛋白的新应用
CN111560438A (zh) * 2020-06-11 2020-08-21 迈杰转化医学研究(苏州)有限公司 检测aml预后相关基因突变的引物组合物、试剂盒及其应用
CN111560438B (zh) * 2020-06-11 2024-01-19 迈杰转化医学研究(苏州)有限公司 检测aml预后相关基因突变的引物组合物、试剂盒及其应用
CN112708675A (zh) * 2020-12-25 2021-04-27 中山大学肿瘤防治中心 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用
CN112626215A (zh) * 2020-12-30 2021-04-09 武汉康圣达医学检验所有限公司 Aml预后相关基因表达检测试剂盒
CN115216541A (zh) * 2021-04-15 2022-10-21 复旦大学附属华山医院 一组白血病标志物及应用
CN113764038A (zh) * 2021-08-31 2021-12-07 华南理工大学 构建骨髓增生异常综合征转白基因预测模型的方法
CN113764038B (zh) * 2021-08-31 2023-08-22 华南理工大学 构建骨髓增生异常综合征转白基因预测模型的方法
CN115323051A (zh) * 2022-02-22 2022-11-11 天津见康华美医学诊断技术有限公司 一种急性髓系白血病检测探针组合物及其应用

Also Published As

Publication number Publication date
CA2867375A1 (en) 2013-09-19
AU2013232379A1 (en) 2014-09-25
EP2825669A4 (en) 2016-02-24
US20150031641A1 (en) 2015-01-29
WO2013138237A9 (en) 2015-01-29
JP2015512630A (ja) 2015-04-30
EP2825669A1 (en) 2015-01-21
WO2013138237A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
CN104508143A (zh) 用于急性髓细胞白血病的诊断、预后和治疗的方法和组合物
JP7526188B2 (ja) ゲノムプロファイリングの類似性
JP7186700B2 (ja) 腫瘍抑制ｆｏｘｏ活性を酸化ストレスから区別する方法
EP2546365B1 (en) Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
CA2860312C (en) Methods and materials for assessing loss of heterozygosity
JP5955557B2 (ja) 膵臓腫瘍形成の根底にある経路および遺伝性の膵癌遺伝子
KR20220130108A (ko) 범-암 백금 반응 예측기
KR20210111254A (ko) 차세대 분자 프로파일링
US10711308B2 (en) Mutation signatures for predicting the survivability of myelodysplastic syndrome subjects
JP6704861B2 (ja) 癌処置のための個別化三剤治療を選択するための方法
CN107034295B (zh) 用于癌症早期诊断和危险度评价的dna甲基化指标及其应用
KR20230011905A (ko) 파노믹 게놈 유병률 점수
AU2021265878A1 (en) Immunotherapy response signature
EP4211690A1 (en) Metastasis predictor
JP2011512785A (ja) ファルネシルトランスフェラーゼ治療に対する急性骨髄性白血病応答を決定する方法
CA2862580A1 (en) Biomarkers of response to nae inhibitors
KR20180107235A (ko) Aml 고 위험군 환자를 식별하는 방법
Gouda et al. Pathogenetic Significance of YBX1 Expression in Acute Myeloid Leukemia Relapse
Hasan et al. Over expression of brain and acute leukemia, cytoplasmic and ETS‐related gene is associated with poor outcome in acute myeloid leukemia
US20250043363A1 (en) Methods and systems for analyzing and utilizing cancer testis antigen burden
WO2022195469A1 (en) Predictive marker for sensitivity to immune checkpoint blockade in prostate cancer and other cancer types
KR20220122219A (ko) Mff의 단일염기다형성을 이용한 소세포폐암의 예후 진단방법
KR20220122220A (ko) Mphosph9의 단일염기다형성을 이용한 소세포폐암의 예후 진단방법
Ahmed Hereditary Breast Cancer in Selected Populations: Screening RECQL Gene in Ontario, Canada, and Exploring BRCA1/2 and PALB2 in the Caribbean
HK1238302A1 (en) Dna methylation biomarker for early detection and risk assessment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150408

WD01 Invention patent application deemed withdrawn after publication